Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Levonorgestrel may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
for Emerres Una is commonly known as 'the morning after Pill'. It is used to reduce the chances of becoming pregnant after unprotected sex or failure of a contraceptive method.
Emerres Una 1.5mg Tablet
Emerres Una contains the active ingredient levonorgestrel, which is a synthetic derivative of the naturally occurring female sex hormone and it is not fully understood how this medicine prevents pregnancy. It is thought to work by preventing ovulation and fertilisation and also by altering the lining of the womb, depending on which stage of the menstrual cycle the woman is at. Emerres Una is not indicated for use before the first menstrual bleeding (menarche). It is estimated that 84 per cent of pregnancies will be prevented if this morning-after Pill is taken within 72 hours of unprotected sex. The tablet is more effective at preventing pregnancy the earlier it is taken, so it is important to take it as soon as possible after unprotected sex, rather than delay to the third day.
e Emerres Una Do not take Emerres Una
You may already be pregnant if:
Nevertheless, your doctor may want to check that the pregnancy is not ectopic (where the baby develops somewhere outside the womb). This is especially important if you develop severe abdominal pain after taking Emerres Una or if you have previously had an ectopic pregnancy, Fallopian tube surgery or pelvic inflammatory disease.
The use of Emerres Una is not advised if:
Breast-feeding Very small amounts of the active ingredient of this medicine may appear in your breast milk. This is not thought to be harmful to the baby. If you are worried you can take your tablet immediately after a breast-feed and avoid nursing for at least 8 hours after taking Emerres Una. In this way you can reduce the amount of active ingredient your baby may take in with the breast milk.
Children and adolescents If you are under 16, you must visit your doctor or family planning clinic to get emergency contraception. If you are worried about sexually transmitted diseases If you did not use a condom (or if it has been torn or slid down) during the intercourse, it might be possible that you have caught a sexually transmitted disease or the HIV virus. This medicine will not protect you against sexually transmitted diseases, only condoms can do this. Ask your doctor, nurse, family planning clinic or pharmacist for advice if you are worried about this. Other medicines and Emerres Una Tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription or herbal medicines. Some medicines may prevent Emerres Una from working effectively. If you have used any of the medicines below during the last 4 weeks, Emerres Una may be less suitable for you. Your doctor may prescribe another type of (non-hormonal) emergency contraceptive, i.e. a copper intrauterine device (Cu-IUD). If this is not an option for you or if you are unable to see your doctor promptly, you can take a double dose of Emerres Una:
Fertility Emerres Una increases the chances of menstruation disturbances which can alter when your egg is released and therefore effect when you can become pregnant, however, there are no fertility data in the long term. Driving and using machines Emerres Una is unlikely to affect your ability to drive a car or use machines. However, if you feel tired or dizzy do not drive or operate machinery. Emerres Una contains lactose Emerres Una contains lactose. If you have been told by your doctor that you have an intolerance to sugars, contact your doctor before taking this medicine.
Emerres Una Always use this medicine exactly as described in the leaflet or as your pharmacist has told you. Check with your doctor or pharmacist if you are not sure. •
Take the tablet as soon as possible, preferably within 12 hours, and no later than 72 hours (3 days) after you have had unprotected sex. Emerres Una can be taken at any time in your menstrual cycle assuming you are not already pregnant or think you may be pregnant. Do not chew but swallow the tablet whole with water. Do not delay taking the tablet. The tablet works best the sooner you take it after having unprotected sex. It can only prevent you becoming pregnant, if you take it within 72 hours of unprotected sex.
Pregnancy, breast-feeding and fertility If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking any medicine.
Once you have taken this medicine, talk to a pharmacist or doctor if your next period is more than 5 days late or you suspect you may be pregnant.
Pregnancy You should not take this medicine if you are already pregnant. If you do become pregnant even after taking this medicine, it is important that you see your doctor. There is no evidence that Emerres Una will harm a baby that develops in your uterus/womb if you use Emerres Una as described.
After you have taken Emerres Una After you have taken Emerres Una, if you want to have sex, and are not using the contraceptive pill, you should use condoms or a cap plus spermicide until your next menstrual period. This is because Emerres Una won't work if you have unprotected sex again, before your next period is due.
If you get any lower stomach pain or discomfort, talk to a doctor straight away.
After you have taken Emerres Una, you are advised to make an appointment to see your doctor about three weeks later, to make sure that Emerres Una has worked. If your period is more than 5 days late or is unusually light or unusually heavy, you should contact your doctor as soon as possible. If you do become pregnant even after taking this medicine, it is important that you see your doctor.
This medicinal product does not require any special storage conditions.
Your doctor can also tell you about longer-term methods of contraception which are more effective in preventing you from getting pregnant.
directly via the Yellow Card Scheme at: www.mhra.gov.uk/ yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.
Emerres Una Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the carton after 'EXP'. The expiry date refers to the last day of that month. M0137LAMUKNAB1-P1-001
If you continue to use regular hormonal contraception such as the contraceptive pill and you do not have a bleed in your pill-free period, see your doctor to make sure you are not pregnant. Your next period after you took Emerres Una After the use of Emerres Una, your period is usually normal and will start at the usual day; however sometimes, this will be a few days later or earlier. If your period starts more than 5 days later than expected, an 'abnormal' bleeding occurs at that time or if you think that you might be pregnant, you should check whether you are pregnant by a pregnancy test. If you take more Emerres Una than you should Although there have been no reports of serious harmful effects from taking too many tablets at once, you may feel sick, actually be sick (vomit), or have vaginal bleeding. You should ask your pharmacist, doctor, practice nurse or family planning clinic for advice, especially if you have been sick, as the tablet may not have worked properly.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
What Emerres Una contains
4. Possible side effects
Manufacturer
Like all medicines, Emerres Una can cause side effects, although not everybody gets them.
Morningside Pharmaceuticals Ltd 5 Pavilion Way Loughborough, UK
Very common (may affect more than 1 in 10 people):
This leaflet was last revised in April 2020.
Common (may affect up to 1 in 10 people):
Emerres Una 1.5 mg tablet comes as tablet containing 1.5mg. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
The active substance in Emerres Una 1.5 mg tablet is levonorgestrel.
Medicines with the same active substance, strength and form include: Emerres 1.5 mg tablet, LoviOne 1.5 mg Tablet, Levonorgestrel 1.5mg Tablets. In total there are 4 equivalent products. They are interchangeable only if your prescriber or pharmacist says so.
This leaflet reproduces the patient information leaflet approved for Emerres Una 1.5 mg tablet, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
Emergency contraception within 72 hours of unprotected sexual intercourse or failure of a contraceptive method.
Levonorgestrel is not recommended for use by young women under 16 years of age without medical supervision.
For oral administration:
One tablet should be taken, as soon as possible, preferably within 12 hours, and no later than 72 hours after unprotected intercourse (see section 5.1).
If vomiting occurs within three hours of taking the tablet, another tablet should be taken immediately. The patient should contact her doctor, family planning clinic or pharmacist for advice and another tablet.
Levonorgestrel can be used at any time during the menstrual cycle unless menstrual bleeding is overdue.
After using emergency contraception it is recommended to use a local barrier method (e.g. condom, diaphragm, spermicide, cervical cap) until the next menstrual period starts. The use of levonorgestrel does not contraindicate the continuation of regular hormonal contraception.
Women who have used enzyme-inducing drugs during the last 4 weeks and need emergency contraception are recommended to use a non-hormonal EC, i.e. Cu-IUD or take a double dose of levonorgestrel (i.e. 2 tablets taken together) for those women unable or unwilling to use Cu-IUD (see section 4.5).
Paediatric population:
There is no relevant use of this medicine for children of prepubertal age in the indication emergency contraception.
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Emergency contraception is an occasional method. It should in no instance replace a regular contraceptive method.
Emergency contraception does not prevent a pregnancy in every instance. If there is uncertainty about the timing of the unprotected intercourse or if the woman has had unprotected intercourse more than 72 hours earlier in the same menstrual cycle, conception may have occurred. Treatment with levonorgestrel following the second act of intercourse may therefore be ineffective in preventing pregnancy. If menstrual periods are delayed by more than 5 days or abnormal bleeding occurs at the expected date of menstrual periods or pregnancy is suspected for any other reason, pregnancy should be excluded.
If pregnancy occurs after treatment with levonorgestrel, the possibility of an ectopic pregnancy should be considered. The absolute risk of ectopic pregnancy is likely to be low, as levonorgestrel prevents ovulation and fertilisation. Ectopic pregnancy may continue, despite the occurrence of uterine bleeding.
Therefore, levonorgestrel is not recommended for patients who are at risk of ectopic pregnancy (previous history of salpingitis or of ectopic pregnancy).
Levonorgestrel is not recommended in patients with severe hepatic dysfunction.
Severe malabsorption syndromes, such as Crohn's disease, might impair the efficacy of levonorgestrel.
This medicinal product contains lactose monohydrate. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine.
Limited and inconclusive data suggest that there may be reduced efficacy of Levonorgestrel with increasing body weight or body mass index (BMI) (see section 5.1 and 5.2). In all women, emergency contraception should be taken as soon as possible after unprotected intercourse, regardless of the woman's body weight or BMI.
After levonorgestrel intake, menstrual periods are usually normal and occur at the expected date. They can sometimes occur earlier or later than expected by a few days.
Women should be advised to make a medical appointment to initiate or adopt a method of regular contraception. If no withdrawal bleed occurs in the next pill-free period following the use of levonorgestrel after regular hormonal contraception, pregnancy should be ruled out.
Repeated administration within a menstrual cycle is not advisable because of the possibility of disturbance of the cycle.
Levonorgestrel is not as effective as a conventional regular method of contraception and is suitable only as an emergency measure. Women who present for repeated courses of emergency contraception should be advised to consider long-term methods of contraception.
Use of emergency contraception does not replace the necessary precautions against sexually transmitted diseases.
The metabolism of levonorgestrel is enhanced by concomitant use of liver enzyme inducers, mainly CYP3A4 enzyme inducers. Concomitant administration of efavirenz has been found to reduce plasma levels of levonorgestrel (AUC) by around 50%.
Drugs suspected of having similar capacity to reduce plasma levels of levonorgestrel include barbiturates (including primidone), phenytoin, carbamazepine, herbal medicines containing Hypericum perforatum (St. John's Wort), rifampicin, ritonavir, rifabutin, griseofulvin.
For women who have used enzyme-inducing drugs in the past 4 weeks and need emergency contraception, the use of non-hormonal emergency contraception (i.e. a Cu-IUD) should be considered. Taking a double dose of levonorgestrel (i.e. 3000 mcg within 72 hours after the unprotected intercourse) is an option for women who are unable or unwilling to use a Cu-IUD, although this specific combination (a double dose of levonorgestrel during concomitant use of an enzyme inducer) has not been studied.
Medicines containing levonorgestrel may increase the risk of cyclosporin toxicity due to possible inhibition of cyclosporin metabolism.
Pregnancy
Levonorgestrel should not be given to pregnant women. It will not interrupt a pregnancy. In the case of continued pregnancy, limited epidemiological data indicate no adverse effects on the foetus but there are no clinical data on the potential consequences if doses greater than 1.5 mg of levonorgestrel are taken (see section
5.3.).
Breast-feeding
Levonorgestrel is secreted into breast milk. Potential exposure of an infant to levonorgestrel can be reduced if the breast-feeding woman takes the tablet immediately after feeding and avoids nursing at least 8 hours following levonorgestrel administration.
Fertility
Levonorgestrel increases the possibility of cycle disturbances which can sometimes lead to earlier or later ovulation date. These changes can result in modified fertility date, however, there are no fertility data in the long term.
No studies on the effect on the ability to drive and use machines have been performed.
The most commonly reported undesirable effect was nausea.
*Bleeding patterns may be temporarily disturbed, but most women will have their next menstrual period within 5-7 days of the expected time.
**If the next menstrual period is more than 5 days overdue, pregnancy should be excluded.
From Post-marketing surveillance additionally, the following adverse events have been reported:
Gastrointestinal disorders
Very rare (<1/10,000): abdominal pain
Skin and subcutaneous tissue disorders
Very rare (<1/10,000): rash, urticaria, pruritus,
Reproductive system and breast disorders
Very rare (<1/10,000): pelvic pain, dysmenorrhoea
General disorders and administration site conditions
Very rare (<1/10,000): face oedema
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
Serious undesirable effects have not been reported following acute ingestion of large doses of oral contraceptives. Overdose may cause nausea, and withdrawal bleeding may occur. There are no specific antidotes and treatment should be symptomatic.
Ask anything about Emerres Una 1.5 mg tablet. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.